STOP ORGANIZATION 's cancer drug MISC prolonged the lives of patients with advanced lung cancer in a clinical trial a result that sent the company 's shares soaring and could pave the way for wider use of what is widely considered the company 's most promising product STOP  In the trial sponsored by the ORGANIZATION patients who received MISC along with standard chemotherapy drugs had a median survival of DURATION NUMBER compared with DURATION NUMBER for those receiving only the chemotherapy STOP 